ATE361915T1 - Die hiv-replikation inhibierende pyrimidine und triazine - Google Patents
Die hiv-replikation inhibierende pyrimidine und triazineInfo
- Publication number
- ATE361915T1 ATE361915T1 AT04737252T AT04737252T ATE361915T1 AT E361915 T1 ATE361915 T1 AT E361915T1 AT 04737252 T AT04737252 T AT 04737252T AT 04737252 T AT04737252 T AT 04737252T AT E361915 T1 ATE361915 T1 AT E361915T1
- Authority
- AT
- Austria
- Prior art keywords
- triazines
- pyrimidines
- hiv replication
- inhibiting hiv
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03100411 | 2003-02-20 | ||
| US47501203P | 2003-06-02 | 2003-06-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE361915T1 true ATE361915T1 (de) | 2007-06-15 |
Family
ID=32910137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04737251T ATE506353T1 (de) | 2003-02-20 | 2004-02-20 | Die hiv-replikation inhibierende indan- substituierte pyrimidine |
| AT04737252T ATE361915T1 (de) | 2003-02-20 | 2004-02-20 | Die hiv-replikation inhibierende pyrimidine und triazine |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04737251T ATE506353T1 (de) | 2003-02-20 | 2004-02-20 | Die hiv-replikation inhibierende indan- substituierte pyrimidine |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7442705B2 (de) |
| EP (2) | EP1603887B1 (de) |
| JP (2) | JP4586013B2 (de) |
| KR (2) | KR20050094896A (de) |
| CN (2) | CN1751031B (de) |
| AP (1) | AP2005003373A0 (de) |
| AR (2) | AR044499A1 (de) |
| AT (2) | ATE506353T1 (de) |
| AU (2) | AU2004213187B2 (de) |
| BR (2) | BRPI0407732A (de) |
| CA (2) | CA2516699C (de) |
| CL (2) | CL2004000303A1 (de) |
| CY (1) | CY1106788T1 (de) |
| DE (2) | DE602004006383T2 (de) |
| DK (1) | DK1597238T3 (de) |
| EA (2) | EA010423B1 (de) |
| ES (1) | ES2287734T3 (de) |
| HR (2) | HRP20050820A2 (de) |
| IL (2) | IL169596A (de) |
| MX (2) | MXPA05008867A (de) |
| MY (1) | MY138308A (de) |
| NO (2) | NO20054312L (de) |
| NZ (2) | NZ542428A (de) |
| PL (2) | PL226954B1 (de) |
| PT (1) | PT1597238E (de) |
| TW (2) | TW200510339A (de) |
| WO (2) | WO2004074262A1 (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| IL166241A0 (en) | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| CL2004000303A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| AU2005231507B2 (en) | 2004-04-08 | 2012-03-01 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| NZ588896A (en) | 2004-08-25 | 2012-05-25 | Targegen Inc | Heterocyclic compounds and methods of use |
| ATE540035T1 (de) | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US8318736B2 (en) * | 2006-12-29 | 2012-11-27 | Janssen R&D Ireland | HIV inhibiting 5,6-substituted pyrimidines |
| US9006243B2 (en) * | 2006-12-29 | 2015-04-14 | Janssen R&D Ireland | HIV inhibiting 6-substituted pyrimidines |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| TW201008933A (en) * | 2008-08-29 | 2010-03-01 | Hutchison Medipharma Entpr Ltd | Pyrimidine compounds |
| GEP20135793B (en) | 2008-09-11 | 2013-03-25 | Pfizer | Heteroaryls amide derivatives and their use as glucokinase activators |
| TW201024281A (en) | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| AR074210A1 (es) * | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
| WO2010103437A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
| AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| US9249124B2 (en) | 2011-03-30 | 2016-02-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase inhibitors and methods of making and using thereof |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| GB201119358D0 (en) | 2011-11-10 | 2011-12-21 | Lewi Paulus J | Disubstituted triazine dimers for treatment and/or prevention of infectious diseases |
| GB201204756D0 (en) | 2012-03-19 | 2012-05-02 | Lewi Paulus J | Triazines with suitable spacers for treatment and/or prevention of HIV infections |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| CN110818690B (zh) | 2016-07-26 | 2021-08-10 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 |
| CN106749203B (zh) * | 2016-11-28 | 2020-04-10 | 洛阳聚慧医药科技有限公司 | 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用 |
| HRP20231310T1 (hr) | 2019-05-10 | 2024-02-02 | Deciphera Pharmaceuticals, Llc | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene |
| HUE065486T2 (hu) | 2019-05-10 | 2024-05-28 | Deciphera Pharmaceuticals Llc | Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai |
| ES3072710T3 (en) | 2019-06-17 | 2026-07-03 | Deciphera Pharmaceuticals Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US5691364A (en) * | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| CZ154398A3 (cs) | 1995-11-23 | 1998-08-12 | Janssen Pharmaceutica N.V. | Pevné směsi cyklodextrinů připravené vytlačováním taveniny |
| NO311614B1 (no) * | 1996-10-01 | 2001-12-17 | Janssen Pharmaceutica Nv | Substituerte diamino-1,3,5-triazinderivater |
| GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| NZ506679A (en) * | 1998-03-27 | 2002-11-26 | Janssen Pharmaceutica Nv | HIV inhibiting pyrimidine derivatives |
| EP0945447A1 (de) * | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituierte 1,3,5-Triazinderivate zur Behandlung von HIV Infektionen |
| ID28376A (id) | 1998-11-10 | 2001-05-17 | Janssen Pharmaceutica Nv | Pirimidina yang menghambat replikasi hiv |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| CA2366932C (en) | 1999-04-15 | 2009-08-25 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| TR200200763T2 (tr) * | 1999-09-24 | 2003-09-22 | Janssen Pharmaceutica N.V. | Antiviral bileşimler |
| MXPA02003436A (es) * | 1999-10-07 | 2002-08-20 | Amgen Inc | Inhibidores de triazina cinasa. |
| CA2406562C (en) | 2000-05-08 | 2009-09-15 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines and triazines |
| WO2002036578A2 (en) * | 2000-10-31 | 2002-05-10 | Lynn Bonham | Triazine derivatives as lpaat-b inhibitors and uses thereof |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| ATE511858T1 (de) * | 2002-02-05 | 2011-06-15 | Astellas Pharma Inc | 2,4,6-triamino-1,3,5-triazin-derivat |
| AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
| ES2373226T3 (es) * | 2002-06-28 | 2012-02-01 | Astellas Pharma Inc. | Derivado de diaminopirimidincarboxamida. |
| IL166241A0 (en) * | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| CL2004000303A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
-
2004
- 2004-02-19 CL CL200400303A patent/CL2004000303A1/es unknown
- 2004-02-19 CL CL200400306A patent/CL2004000306A1/es unknown
- 2004-02-20 NZ NZ542428A patent/NZ542428A/en unknown
- 2004-02-20 EP EP04737251A patent/EP1603887B1/de not_active Expired - Lifetime
- 2004-02-20 HR HR20050820A patent/HRP20050820A2/xx not_active Application Discontinuation
- 2004-02-20 MX MXPA05008867A patent/MXPA05008867A/es active IP Right Grant
- 2004-02-20 AT AT04737251T patent/ATE506353T1/de not_active IP Right Cessation
- 2004-02-20 AU AU2004213187A patent/AU2004213187B2/en not_active Ceased
- 2004-02-20 DE DE602004006383T patent/DE602004006383T2/de not_active Expired - Lifetime
- 2004-02-20 AT AT04737252T patent/ATE361915T1/de not_active IP Right Cessation
- 2004-02-20 AP AP2005003373A patent/AP2005003373A0/xx unknown
- 2004-02-20 DE DE602004032321T patent/DE602004032321D1/de not_active Expired - Lifetime
- 2004-02-20 US US10/545,358 patent/US7442705B2/en not_active Expired - Lifetime
- 2004-02-20 PL PL378064A patent/PL226954B1/pl unknown
- 2004-02-20 HR HR20050821A patent/HRP20050821A2/xx not_active Application Discontinuation
- 2004-02-20 KR KR1020057014231A patent/KR20050094896A/ko not_active Ceased
- 2004-02-20 KR KR1020057014648A patent/KR20050099994A/ko not_active Ceased
- 2004-02-20 EP EP04737252A patent/EP1597238B1/de not_active Expired - Lifetime
- 2004-02-20 ES ES04737252T patent/ES2287734T3/es not_active Expired - Lifetime
- 2004-02-20 AU AU2004213186A patent/AU2004213186B2/en not_active Ceased
- 2004-02-20 PT PT04737252T patent/PT1597238E/pt unknown
- 2004-02-20 WO PCT/EP2004/050177 patent/WO2004074262A1/en not_active Ceased
- 2004-02-20 PL PL378136A patent/PL227295B1/pl unknown
- 2004-02-20 DK DK04737252T patent/DK1597238T3/da active
- 2004-02-20 JP JP2006502041A patent/JP4586013B2/ja not_active Expired - Fee Related
- 2004-02-20 CN CN2004800043209A patent/CN1751031B/zh not_active Expired - Fee Related
- 2004-02-20 AR ARP040100548A patent/AR044499A1/es not_active Application Discontinuation
- 2004-02-20 WO PCT/EP2004/050175 patent/WO2004074261A1/en not_active Ceased
- 2004-02-20 CA CA2516699A patent/CA2516699C/en not_active Expired - Fee Related
- 2004-02-20 MX MXPA05008866A patent/MXPA05008866A/es active IP Right Grant
- 2004-02-20 JP JP2006502042A patent/JP4586014B2/ja not_active Expired - Fee Related
- 2004-02-20 TW TW093104175A patent/TW200510339A/zh unknown
- 2004-02-20 CA CA2516589A patent/CA2516589C/en not_active Expired - Fee Related
- 2004-02-20 CN CNB2004800043162A patent/CN100572364C/zh not_active Expired - Fee Related
- 2004-02-20 BR BRPI0407732-6A patent/BRPI0407732A/pt not_active Application Discontinuation
- 2004-02-20 EA EA200501326A patent/EA010423B1/ru not_active IP Right Cessation
- 2004-02-20 NZ NZ541601A patent/NZ541601A/en unknown
- 2004-02-20 TW TW093104173A patent/TW200500346A/zh unknown
- 2004-02-20 MY MYPI20040575A patent/MY138308A/en unknown
- 2004-02-20 BR BRPI0407741A patent/BRPI0407741B8/pt not_active IP Right Cessation
- 2004-02-20 EA EA200501327A patent/EA011256B1/ru not_active IP Right Cessation
- 2004-02-20 AR ARP040100549A patent/AR044500A1/es not_active Application Discontinuation
- 2004-02-20 US US10/545,719 patent/US7585870B2/en not_active Expired - Lifetime
-
2005
- 2005-07-07 IL IL169596A patent/IL169596A/en active IP Right Grant
- 2005-07-12 IL IL169647A patent/IL169647A/en active IP Right Grant
- 2005-09-19 NO NO20054312A patent/NO20054312L/no not_active Application Discontinuation
- 2005-09-19 NO NO20054311A patent/NO20054311L/no not_active Application Discontinuation
-
2007
- 2007-08-03 CY CY20071101039T patent/CY1106788T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004006383D1 (de) | Die hiv-replikation inhibierende pyrimidine und triazine | |
| ATE376420T1 (de) | Mikrobizide pyrimidine oder triazine zur vorbeugung der sexuellen übertragung von hiv | |
| ATE448210T1 (de) | Pyrimidin, triazin und pyrazinderivate als glutamatrezeptoren | |
| NO20024308L (no) | Arylsubstituerte pyridiner, pyrimidiner og triaziner og deres anvendelse | |
| LT3808743T (lt) | Živ replikaciją slopinantys pirimidinai | |
| DE50305279D1 (de) | 4-trifluormethylpyrazolyl substituierte pyridine und pyrimidine | |
| DE50213202D1 (de) | Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel | |
| PL375390A1 (en) | 4-trifluoromethylpyrazolyl substituted pyridines and pyrimidines | |
| IL180959A0 (en) | Hiv inhibiting 5-heterocyclyl pyrimidines | |
| ATE387446T1 (de) | Pyrido(2,3-d)pyrimidin-2,4-diamine als pde-2- inhibitoren | |
| ZA200702656B (en) | HIV inhibiting 5-substituted pyrimidines | |
| ATE350370T1 (de) | 2-substituierte pyrimidine | |
| SE0301654D0 (sv) | Novel compounds | |
| ZA200506622B (en) | HIV replication inhibiting pyrimidines and triazines | |
| GB0323137D0 (en) | 2,4,6- Trisubstituted pyrimidines and their different uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1597238 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |